Eiger BioPharmaceuticals, Inc

(NASDAQ:EIGR)

Latest On Eiger BioPharmaceuticals, Inc (EIGR):

Date/Time Type Description Signal Details
2023-05-11 19:17 ESTNewsEiger BioPharmaceuticals GAAP EPS of -$0.52 misses by $0.12, revenue of $4.1M beats by $0.28MN/A
2023-04-13 20:11 ESTNewsEiger BioPharmaceuticals appoints William Kachioff as CFON/A
2023-03-16 17:18 ESTNewsEiger BioPharmaceuticals GAAP EPS of -$0.57 misses by $0.03, revenue of $2.69M misses by $1.73MN/A
2023-03-10 22:47 ESTNewsSangamo, Protagonist, and Eiger among biotechs with exposure to Silicon Valley BankN/A
2023-02-17 16:00 ESTNewsEiger BioPharmaceuticals: The Results Are In - The CEO And The CFO Are OutN/A
2023-02-09 10:02 ESTNewsEiger gains as journal publishes late-stage data for COVID therapyN/A
2022-12-16 02:59 ESTNewsEiger BioPharmaceuticals CEO David Cory resigns, David Apelian named Interim CEON/A
2022-12-09 00:53 ESTNewsEiger plunges 70% after late-stage data for chronic hepatitis candidateN/A
2022-11-26 06:59 ESTNewsEiger BioPharmaceuticals: A Compelling High Beta StoryN/A
2022-11-04 02:05 ESTNewsEiger BioPharmaceuticals GAAP EPS of -$0.62 misses by $0.10, revenue of $4.02M misses by $0.24MN/A
2022-11-04 02:05 ESTNewsEiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call TranscriptN/A
2022-11-03 08:26 ESTNewsEiger BioPharmaceuticals Q3 2022 Earnings PreviewN/A
2022-10-17 01:26 ESTNewsCiti lists four more value-creating events in biotech for this yearN/A
2022-10-05 21:04 ESTNewsEiger sheds ~20% on abandonment of EUA request for COVID therapyN/A
2022-09-07 01:12 ESTNewsEiger falls 21% amid uncertainty over regulatory path for COVID-19 therapyN/A
2022-08-07 00:13 ESTNewsEiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-05 02:15 ESTNewsEiger BioPharmaceuticals GAAP EPS of -$0.51 beats by $0.11, revenue of $4.09M misses by $0.99MN/A
2022-08-03 20:09 ESTNewsEiger BioPharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-26 15:45 ESTNewsEiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 CatalystN/A
2022-07-20 21:22 ESTNewsEuropean Commission approves Eiger BioPharmaceuticals' progeria therapy ZokinvyN/A
2022-06-08 03:08 ESTNewsEiger BioPharmaceuticals enter $75M term loan and $5M stock repurchase agreement to bolster cash positionN/A
2022-05-21 04:50 ESTNewsEU drug regulator panel recommends approval for Eiger BioPharma's progeria therapyN/A
2022-05-08 14:15 ESTNewsEiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 02:25 ESTNewsEiger BioPharmaceuticals GAAP EPS of -$0.64 in-line, revenue of $2.67M misses by $1.38MN/A
2022-05-06 02:25 ESTNewsEiger BioPharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-05 02:49 ESTNewsEiger BioPharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-25 20:46 ESTNewsEiger avexitide shows promise in phase 2 trial in children with hyperinsulinismN/A
2022-04-18 14:43 ESTNewsEiger BioPharmaceuticals appoints Christopher Kurtz as Chief Technical OfficerN/A
2022-04-06 15:01 ESTNewsEiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The HorizonN/A
2022-03-18 18:14 ESTNewsEiger says COVID-19 therapy cut hospitalization risk by 50% in mostly vaccinated adultsN/A
2022-03-15 02:47 ESTNewsEiger extends gains with no impact to trials in Russia and UkraineN/A
2022-03-11 10:32 ESTNewsEiger BioPharmaceuticals GAAP EPS of -$0.64 misses by $0.01, revenue of $3.36M misses by $0.03MN/A
2022-03-11 10:32 ESTNewsEiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory On Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-11 10:32 ESTNewsEiger BioPharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-09 23:00 ESTNewsEiger BioPharmaceuticals Q4 2021 Earnings PreviewN/A
2022-01-07 04:16 ESTNewsEiger Biopharmaceuticals provides pipeline updates for 2022N/A
2021-12-26 17:49 ESTNewsEiger Pharma: HDV Approval In 2023 Is A Major CatalystN/A
2021-11-23 21:22 ESTNewsEiger Biopharmaceuticals (EIGR) AT HDV KOL Event - SlideshowN/A
2021-11-12 20:27 ESTNewsWarning: EIGR is at high risk of performing badlyN/A
2021-11-05 05:10 ESTNewsEiger BioPharmaceuticals EPS misses by $0.09, beats on revenueN/A
2021-11-05 05:09 ESTNewsEiger BioPharmaceuticals' (EIGR) CEO David Cory on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 11:34 ESTNewsEiger BioPharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-01 18:45 ESTNewsEiger completes enrollment in late-stage Lonafarnib hepatitis delta virus studyN/A
2021-09-21 17:13 ESTNewsEiger gets DSMB backing to continue enrollment in late-stage COVID-19 trialN/A
2021-08-08 11:38 ESTNewsEiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 02:12 ESTNewsEiger shares rise on FDA Breakthrough Therapy status for avexitideN/A
2021-08-06 02:09 ESTNewsEiger BioPharmaceuticals EPS misses by $0.02, misses on revenueN/A
2021-07-21 06:29 ESTNewsEiger shares rise on mid-stage avexitide congenital hyperinsulinism study resultsN/A
2021-07-21 06:28 ESTNewsEiger Bio pops 7% after securing NORD Rare Impact Award for ZokinvyN/A
2021-07-21 06:21 ESTNewsEiger Biopharmaceuticals starts dosing in late-stage COVID-19 trialN/A

About Eiger BioPharmaceuticals, Inc (EIGR):

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

EIGR Quotes by TradingView

See Advanced Chart

General

  • Name Eiger BioPharmaceuticals, Inc
  • Symbol EIGR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 28
  • Last Split Factor1:15
  • Last Split Date2016-03-23
  • Fiscal Year EndDecember
  • IPO Date2014-01-30
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.eigerbio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 3.51
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.36
  • Next Year EPS Estimate -$1.71
  • Next Quarter EPS Estimate -$0.05
  • Return on Assets -31%
  • Return on Equity -86%
  • Earnings Per Share -$3.65
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 316.98 million
  • EBITDA -66959000
  • Analyst Target Price $31.67
  • Book Value Per Share $2.81
View More

Share Statistics

  • Shares Outstanding 33.9 million
  • Shares Float 29.02 million
  • % Held by Insiders 127%
  • % Held by Institutions 74.5%
  • Shares Short 1.55 million
  • Shares Short Prior Month 1.58 million
  • Short Ratio 6.55
  • Short % of Float 5%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.41
  • 52 Week High $13.99
  • 52 Week Low $5.28
  • 50 Day Moving Average 10.57
  • 200 Day Moving Average 10.08
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Eiger BioPharmaceuticals, Inc (EIGR) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eiger BioPharmaceuticals, Inc (EIGR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.57$0.38-249.45%
2020-09-302020-11-05$N/A-$0.52-$0.6317.04%
2020-06-302020-08-06$N/A-$0.60-$0.7318.02%
2020-03-312020-05-07$N/A-$0.62-$0.7921.23%
2019-12-312020-03-13$N/A-$0.69-$0.8014.07%
2019-09-302019-11-07$N/A-$0.76-$0.74-2.48%
2019-06-302019-08-08$N/A-$0.75-$0.74-1.53%
2019-03-312019-05-09$N/A-$0.90-$0.988.4%
2018-12-312019-03-14$N/A-$0.92-$0.82-11.65%
2018-09-302018-11-09$N/A-$1.20-$0.77-56.66%
2018-06-302018-08-10$N/A-$0.82-$0.852.96%
2018-03-312018-05-11$N/A-$0.84-$1.0922.82%
2017-12-312018-03-09$N/A-$1.09-$1.05-3.61%
2017-09-302017-11-09$N/A-$1.10-$1.3417.76%
2017-06-302017-08-11$N/A-$1.33-$1.31-1.72%
2017-03-312017-05-12$N/A-$1.34-$1.350.74%
2016-12-312017-03-23$N/A-$1.26-$1.388.91%
2016-09-302016-11-08$N/A-$1.49-$1.22-21.8%
2016-06-302016-08-10$N/A-$1.87-$1.10-70%
2016-03-312016-05-16$N/A-$10.42-$2.83-268.2%
2015-09-302015-11-09$N/A-$2.85-$3.3013.64%
2015-06-302015-08-11$N/A-$8.40-$4.72-77.97%
2015-03-312015-05-14$N/A-$10.65-$6.78-57.08%
2014-12-312015-03-31$N/A-$7.50-$5.40-38.89%
2014-09-302014-11-12$N/A-$6.00-$5.64-6.38%
2014-06-302014-08-07$N/A-$5.70-$5.771.21%
2014-03-312014-05-14$N/A-$8.70-$9.003.33%
2013-12-312014-03-31-$116.55-$7.05-1553.19%

Eiger BioPharmaceuticals, Inc (EIGR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Eiger BioPharmaceuticals, Inc (EIGR) Chart:

Eiger BioPharmaceuticals, Inc (EIGR) News:

Below you will find a list of latest news for Eiger BioPharmaceuticals, Inc (EIGR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eiger BioPharmaceuticals, Inc (EIGR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-07-192.50.05CALL1 110FALSE00
2024-07-1950CALL0 00FALSE00
2024-07-197.50CALL0 00FALSE00
2024-07-192.50PUT0 00TRUE00
2024-07-1950PUT0 0316.7TRUE00
2024-07-197.50PUT0 0358.64TRUE00

Latest EIGR Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST44$5.26
Jun 13, 2022 7:59 PM EST42$5.26
Jun 13, 2022 7:59 PM EST100$5.26
Jun 13, 2022 7:59 PM EST93$5.25
Jun 13, 2022 7:59 PM EST7$5.25

Eiger BioPharmaceuticals, Inc (EIGR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520171440/0001193125-20-171440-index.htm
2019-12-23UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1305253/000000000019016767/0000000000-19-016767-index.htm
2019-01-31SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000005341719000023/0000053417-19-000023-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000083423720008122/0000834237-20-008122-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000089924318027169/0000899243-18-027169-index.htm
2018-10-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000090266418003855/0000902664-18-003855-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000090266420000957/0000902664-20-000957-index.htm
2019-06-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000091957419004168/0000919574-19-004168-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000091957420001123/0000919574-20-001123-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000093583619000126/0000935836-19-000126-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000093583620000145/0000935836-20-000145-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000110465919008745/0001104659-19-008745-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000110465920021903/0001104659-20-021903-index.htm
2019-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000113777419000043/0001137774-19-000043-index.htm
2018-10-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000114420418055387/0001144204-18-055387-index.htm
2018-10-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000114420418055388/0001144204-18-055388-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000117891319000438/0001178913-19-000438-index.htm
2018-06-11DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1305253/000119312518189594/0001193125-18-189594-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518193255/0001193125-18-193255-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518247356/0001193125-18-247356-index.htm
2018-08-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518250675/0001193125-18-250675-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518304210/0001193125-18-304210-index.htm
2018-10-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1305253/000119312518304289/0001193125-18-304289-index.htm
2018-10-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1305253/000119312518305424/0001193125-18-305424-index.htm
2018-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518305472/0001193125-18-305472-index.htm
2018-10-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1305253/000119312518305844/0001193125-18-305844-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518322746/0001193125-18-322746-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518323748/0001193125-18-323748-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518341240/0001193125-18-341240-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312518353484/0001193125-18-353484-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519003763/0001193125-19-003763-index.htm
2019-01-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1305253/000119312519020636/0001193125-19-020636-index.htm
2019-02-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1305253/000119312519029536/0001193125-19-029536-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1305253/000119312519039523/0001193125-19-039523-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519069306/0001193125-19-069306-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519074779/0001193125-19-074779-index.htm
2019-03-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1305253/000119312519074970/0001193125-19-074970-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519106558/0001193125-19-106558-index.htm
2019-04-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1305253/000119312519109081/0001193125-19-109081-index.htm
2019-04-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1305253/000119312519110948/0001193125-19-110948-index.htm
2019-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519113453/0001193125-19-113453-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1305253/000119312519122466/0001193125-19-122466-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1305253/000119312519122480/0001193125-19-122480-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519142983/0001193125-19-142983-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519150558/0001193125-19-150558-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519171309/0001193125-19-171309-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519216853/0001193125-19-216853-index.htm
2019-08-088-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519217043/0001193125-19-217043-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519287307/0001193125-19-287307-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312519315318/0001193125-19-315318-index.htm
2019-12-20S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1305253/000119312519321040/0001193125-19-321040-index.htm
2019-12-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1305253/000119312519323545/0001193125-19-323545-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520001790/0001193125-20-001790-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520002612/0001193125-20-002612-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520072305/0001193125-20-072305-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1305253/000119312520072874/0001193125-20-072874-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520081589/0001193125-20-081589-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1305253/000119312520123158/0001193125-20-123158-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1305253/000119312520123187/0001193125-20-123187-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520136236/0001193125-20-136236-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520146138/0001193125-20-146138-index.htm
2020-05-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1305253/000119312520155782/0001193125-20-155782-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520171440/0001193125-20-171440-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520211938/0001193125-20-211938-index.htm
2020-08-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1305253/000119312520212104/0001193125-20-212104-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520269865/0001193125-20-269865-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000119312520286830/0001193125-20-286830-index.htm
2018-11-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919118060179/0001209191-18-060179-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919118060345/0001209191-18-060345-index.htm
2018-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919118061728/0001209191-18-061728-index.htm
2018-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919118063781/0001209191-18-063781-index.htm
2018-12-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919118064161/0001209191-18-064161-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119002201/0001209191-19-002201-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119003030/0001209191-19-003030-index.htm
2019-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119003038/0001209191-19-003038-index.htm
2019-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119007882/0001209191-19-007882-index.htm
2019-03-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021276/0001209191-19-021276-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021277/0001209191-19-021277-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021279/0001209191-19-021279-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021280/0001209191-19-021280-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021281/0001209191-19-021281-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021282/0001209191-19-021282-index.htm
2019-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021283/0001209191-19-021283-index.htm
2019-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021284/0001209191-19-021284-index.htm
2019-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021285/0001209191-19-021285-index.htm
2019-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119021286/0001209191-19-021286-index.htm
2019-04-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119025562/0001209191-19-025562-index.htm
2019-04-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119025563/0001209191-19-025563-index.htm
2019-04-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119025564/0001209191-19-025564-index.htm
2019-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119025623/0001209191-19-025623-index.htm
2019-04-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119026233/0001209191-19-026233-index.htm
2019-05-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119033497/0001209191-19-033497-index.htm
2019-05-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119033500/0001209191-19-033500-index.htm
2019-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119048804/0001209191-19-048804-index.htm
2019-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119048805/0001209191-19-048805-index.htm
2019-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919119048817/0001209191-19-048817-index.htm
2020-01-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120003153/0001209191-20-003153-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120005548/0001209191-20-005548-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120005872/0001209191-20-005872-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018973/0001209191-20-018973-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018977/0001209191-20-018977-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018979/0001209191-20-018979-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018984/0001209191-20-018984-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018988/0001209191-20-018988-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018991/0001209191-20-018991-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120018995/0001209191-20-018995-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120019001/0001209191-20-019001-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120019003/0001209191-20-019003-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120019004/0001209191-20-019004-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120019682/0001209191-20-019682-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120019685/0001209191-20-019685-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1305253/000120919120046449/0001209191-20-046449-index.htm
2019-11-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1305253/000121390019023939/0001213900-19-023939-index.htm
2018-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459018021197/0001564590-18-021197-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459018028934/0001564590-18-028934-index.htm
2019-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1305253/000156459019007830/0001564590-19-007830-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459019018009/0001564590-19-018009-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459019030837/0001564590-19-030837-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/0001564590-19-041773-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1305253/000156459020010645/0001564590-20-010645-index.htm
2020-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1305253/000156459020014794/0001564590-20-014794-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459020022884/0001564590-20-022884-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459020037833/0001564590-20-037833-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1305253/000156459020051341/0001564590-20-051341-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1305253/000161577419002505/0001615774-19-002505-index.htm
2019-12-31EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1305253/999999999520000006/9999999995-20-000006-index.htm
2018-08-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1305253/999999999718007372/9999999997-18-007372-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1305253/999999999718009617/9999999997-18-009617-index.htm

Eiger BioPharmaceuticals, Inc (EIGR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eiger BioPharmaceuticals, Inc (EIGR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 127%
Institutional Ownership: 7450%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-20Thomas John DietzDirectorBuy5,000.009.9849,900.0010,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919118063781/0001209191-18-063781-index.htm
2018-09-05James P ShafferChief Business OfficerBuy1,500.007.9511,921.2511,421.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021285/0001209191-19-021285-index.htm
2019-04-22Sriram RyaliChief Financial OfficerBuy1,250.0011.0813,852.751,250.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119025564/0001209191-19-025564-index.htm
2019-03-05James P ShafferChief Business OfficerBuy1,500.007.9511,921.2512,921.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021285/0001209191-19-021285-index.htm
2018-10-18PARTNERS X LP INTERWEST10% Share HolderSell26,465.0012.00317,606.471,362,327.00https://www.sec.gov/Archives/edgar/data/1305253/000089924318027169/0000899243-18-027169-index.htm
2018-10-18PARTNERS X LP INTERWEST10% Share HolderSell210,800.0012.072,544,714.361,388,792.00https://www.sec.gov/Archives/edgar/data/1305253/000089924318027169/0000899243-18-027169-index.htm
2019-09-05Sriram RyaliChief Financial OfficerBuy149.009.371,395.681,399.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119048805/0001209191-19-048805-index.htm
2019-09-05James P ShafferChief Business OfficerBuy1,500.007.9511,921.2514,421.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119048817/0001209191-19-048817-index.htm
2018-11-27Eldon C. III MayerDirectorBuy7,500.009.9274,407.5015,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919118060179/0001209191-18-060179-index.htm
2019-04-22Thomas John DietzDirectorBuy5,000.0011.0555,250.0015,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119025563/0001209191-19-025563-index.htm
2020-03-05James P ShafferChief Business OfficerBuy1,500.007.3110,965.0015,921.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120019004/0001209191-20-019004-index.htm
2020-03-05Sriram RyaliChief Financial OfficerBuy229.007.311,673.991,628.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120019001/0001209191-20-019001-index.htm
2019-04-23Thomas John DietzDirectorBuy5,000.0011.1055,495.0020,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119025623/0001209191-19-025623-index.htm
2001-11-28Eldon C. III MayerDirectorBuy6,000.0010.0760,447.0021,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919118060179/0001209191-18-060179-index.htm
2020-01-10Thomas John DietzDirectorBuy4,000.0013.9455,760.0024,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120003153/0001209191-20-003153-index.htm
2018-11-29Eldon C. III MayerDirectorBuy4,000.0010.2140,840.0025,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919118060345/0001209191-18-060345-index.htm
2020-03-12Thomas John DietzDirectorBuy5,000.0029,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018977/0001209191-20-018977-index.htm
2020-01-24Eldon C. III MayerEx VP & Chief Commerc. OfficerBuy5,000.0013.5267,602.5030,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120005548/0001209191-20-005548-index.htm
2020-03-16Thomas John DietzDirectorBuy1,000.004.954,950.0030,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120019685/0001209191-20-019685-index.htm
2020-03-12Jeffrey S GlennDirectorBuy5,000.0036,355.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018984/0001209191-20-018984-index.htm
2020-01-31Eldon C. III MayerEx VP & Chief Commerc. OfficerBuy7,500.0037,500.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120005872/0001209191-20-005872-index.htm
2019-04-22Stephana Eilene PattonOfficerBuy1,000.0011.0311,030.004,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119025562/0001209191-19-025562-index.htm
2020-03-05Stephana Eilene PattonOfficerBuy820.007.315,994.204,820.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018995/0001209191-20-018995-index.htm
2020-08-12Jeffrey S GlennDirectorBuy500.0011.285,637.50500.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120046449/0001209191-20-046449-index.htm
2020-03-12Amit SachdevDirectorBuy5,000.005,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120019003/0001209191-20-019003-index.htm
2020-03-12Christine MurrayDirectorBuy5,000.005,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018991/0001209191-20-018991-index.htm
2020-03-12David ApelianDirectorBuy5,000.005,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018973/0001209191-20-018973-index.htm
2020-03-12Evan LohDirectorBuy5,000.005,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018988/0001209191-20-018988-index.htm
2020-08-12Jeffrey S GlennDirectorBuy4,500.0011.4451,465.155,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120046449/0001209191-20-046449-index.htm
2018-12-06Thomas John DietzDirectorBuy5,000.0011.2656,300.005,000.00https://www.sec.gov/Archives/edgar/data/1305253/000120919118061728/0001209191-18-061728-index.htm
2019-02-04David A CoryPresident and CEOBuy227.0014.133,207.5158,678.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119007882/0001209191-19-007882-index.htm
2017-03-06David A CoryPresident and CEOBuy1,325.008.2010,868.3160,003.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021284/0001209191-19-021284-index.htm
2017-09-05David A CoryPresident and CEOBuy1,500.009.9014,853.7561,503.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021284/0001209191-19-021284-index.htm
2018-03-05David A CoryPresident and CEOBuy1,500.008.0312,048.7563,003.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021284/0001209191-19-021284-index.htm
2018-09-05David A CoryPresident and CEOBuy1,500.007.9511,921.2564,503.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021284/0001209191-19-021284-index.htm
2019-03-05David A CoryPresident and CEOBuy1,500.007.9511,921.2566,003.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021284/0001209191-19-021284-index.htm
2019-02-04David A CoryPresident and CEOBuy343.0011.263,862.1866,346.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119026233/0001209191-19-026233-index.htm
2020-03-16Jeffrey S GlennDirectorBuy30,000.005.03150,813.0066,355.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120019682/0001209191-20-019682-index.htm
2019-09-05David A CoryPresident and CEOBuy1,500.007.9511,921.2567,846.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119048804/0001209191-19-048804-index.htm
2017-03-06James P ShafferChief Business OfficerBuy1,301.008.2010,671.456,921.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021285/0001209191-19-021285-index.htm
2020-03-05David A CoryPresident and CEOBuy1,500.007.3110,965.0069,346.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120018979/0001209191-20-018979-index.htm
2020-08-11Jeffrey S GlennDirectorBuy5,000.0011.4957,463.5071,355.00https://www.sec.gov/Archives/edgar/data/1305253/000120919120046449/0001209191-20-046449-index.htm
2018-11-26Eldon C. III MayerDirectorBuy7,500.009.7573,143.007,500.00https://www.sec.gov/Archives/edgar/data/1305253/000120919118060179/0001209191-18-060179-index.htm
2017-09-05James P ShafferChief Business OfficerBuy1,500.009.9014,853.758,421.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021285/0001209191-19-021285-index.htm
2018-03-05James P ShafferChief Business OfficerBuy1,500.008.0312,048.759,921.00https://www.sec.gov/Archives/edgar/data/1305253/000120919119021285/0001209191-19-021285-index.htm